Novartis Executive Says Generic-Quality Issues Lead To Fewer Players
This article was originally published in PharmAsia News
Executive Summary
The CEO of the Sandoz unit of Novartis said he expects makers of branded drugs to benefit from what he sees as a shake-out of the generics industry in the wake of quality problems in India, where 40% of the world's supply is produced.